941 related articles for article (PubMed ID: 21790999)
1. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
2. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
4. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
7. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.
Lu X; Tang X; Guo W; Ren T; Zhao H
J Surg Oncol; 2010 Dec; 102(7):821-6. PubMed ID: 20812347
[TBL] [Abstract][Full Text] [Related]
9. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
10. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
11. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Chapuy B; Schuelper N; Panse M; Dohm A; Hand E; Schroers R; Truemper L; Wulf GG
Br J Haematol; 2011 Feb; 152(4):401-12. PubMed ID: 21689083
[TBL] [Abstract][Full Text] [Related]
12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
13. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Wang L; Jia D; Duan F; Sun Z; Liu X; Zhou L; Sun L; Ren S; Ruan Y; Gu J
Biochem Biophys Res Commun; 2012 Jun; 422(4):687-92. PubMed ID: 22634008
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction pathways in Burkitt's lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin.
Shlapatska LM; Berdova GG; Kovalevska LM; Kulyk GI; Klein G; Sidorenko SP; Chekhun VF
Exp Oncol; 2004 Sep; 26(3):210-6. PubMed ID: 15494689
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
16. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
17. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.
Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC
Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064
[TBL] [Abstract][Full Text] [Related]
18. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
20. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]